文献速递肾小球疾病慢性肾脏病

白细胞趋化因子2(ALECT2)淀粉样变的诊断、发病机制与结局

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究首次报告欧洲中心ALECT2淀粉样变队列,24例非白种人患者占肾淀粉样变1.3%,诊断中位年龄62岁,中位eGFR 33 mL/min/1.73 m2、蛋白尿0.5 g/24 h,中位随访4.8年,4例死亡、4例进展至终末期肾病,中位肾脏生存8.2年。

要点

  • ALECT2淀粉样变在非白种人中占肾淀粉样变1.3%,诊断依赖肾组织免疫组化。
  • 诊断时肾功能已中度下降(中位eGFR 33),蛋白尿轻(中位0.5 g/24 h)。
  • 病程相对良性,中位肾脏生存8.2年,GFR年均下降4.2 mL/min。

核心结论

  • ALECT2淀粉样变是一种相对良性的肾淀粉样变类型,与缓慢的GFR下降相关,可经肾组织学可靠诊断。

研究设计与样本

  • 研究为英国国家淀粉样变中心1994至2015年系统随访的所有ALECT2淀粉样变患者的病例系列。
  • 共纳入24例非白种人患者,占该中心活检证实的肾淀粉样变患者的1.3%。

主要发现

  • 诊断中位年龄62岁,中位eGFR 33 mL/min/1.73 m2,中位蛋白尿0.5 g/24 h。
  • 24例中11例经血清淀粉样P成分(SAP)闪烁显像发现肝脏淀粉样沉积,但无显著肝功能异常。
  • 无患者有心脏淀粉样变或淀粉样神经病变证据。
  • 中位随访4.8年(范围0.5-15.2年),4例死亡,4例进展至终末期肾病。
  • GFR平均下降速率4.2 mL/min/年(范围0.5-9.6),诊断后中位肾脏生存8.2年,系列SAP扫描示全身淀粉样负荷变化很小或无变化。

关键数值与推荐

  • 肾组织学诊断,免疫组化染色可 definitive 确定ALECT2纤维类型。
  • 诊断时中位eGFR 33 mL/min/1.73 m2、中位蛋白尿0.5 g/24 h。
  • 中位随访4.8年,4例死亡、4例进展至终末期肾病,中位肾脏生存8.2年。

临床怎么用

  • 对非白种人肾淀粉样变患者应考虑ALECT2,肾活检免疫组化可明确分型。
  • 诊断时需评估肾功能和蛋白尿,并可用SAP闪烁显像评估肝脾等器官受累。
  • ALECT2病程相对缓慢,管理可侧重监测GFR下降和肾脏生存。

局限性

  • ALECT2淀粉样变仅见于非白种人队列,分子基础及人群限制因素尚未确定。
  • 样本量较小(24例),随访时间跨度大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Renal biopsy series from North America suggest that leucocyte chemotactic factor 2 (ALECT2) amyloid is the third most common type of renal amyloid. We report the first case series from a European Centre of prevalence, clinical presentation and diagnostic findings in ALECT2 amyloidosis and report long-term patient and renal outcomes for the first time. METHODS: We studied the clinical features, diagnostic investigations and the outcome of all patients with ALECT2 amyloidosis followed systematically at the UK National Amyloidosis Centre (NAC) between 1994 and 2015. RESULTS: Twenty-four patients, all non-Caucasian, were diagnosed with ALECT2 amyloidosis representing 1.3% of all patients referred to the NAC with biopsy-proved renal amyloid. Diagnosis was made at median age of 62 years, usually from renal histology; immunohistochemical staining was definitive for ALECT2 fibril type. Median estimated glomerular filtration rate (GFR) at diagnosis was 33 mL/min/1.73 m2 and median proteinuria was 0.5 g/24 h. Hepatic amyloid was evident on serum amyloid P component (SAP) scintigraphy in 11/24 cases but was not associated with significant derangement of liver function. No patient had evidence of cardiac amyloidosis or amyloid neuropathy. Median follow-up was 4.8 (range 0.5-15.2) years, during which four patients died and four progressed to end-stage renal disease. The mean rate of GFR loss was 4.2 (range 0.5-9.6) mL/min/year and median estimated renal survival from diagnosis was 8.2 years. Serial SAP scans revealed little or no change in total body amyloid burden. CONCLUSIONS: ALECT2 amyloidosis is a relatively benign type of renal amyloid, associated with a slow GFR decline, which is reliably diagnosed on renal histology. Neither the molecular basis nor the factors underlying the apparent restriction of ALECT2 amyloidosis to non-Caucasian populations have been determined.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rezk T, Gilbertson JA, Rowczenio D, et al. Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrol Dial Transplant. 2018. PMID: 29401357. doi:10.1093/ndt/gfw375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。